For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- Jury Finds Enhertu Infringes Seagen Patent, Awards US$41.8 Million in Damages
April 12, 2022
- CEPI to Fund NEC’s AI-Based Coronavirus Vaccine Development
April 12, 2022
- Pertussis, Diphtheria, Tetanus, Polio, Hib Vaccine Filed in Japan: BIKEN/Mitsubishi
April 12, 2022
- Astellas, GSK, 2 Other Firms Log 10%-Plus Drop in Workforce: Jiho Poll
April 11, 2022
- CMS Decision De-Facto Denial of All Medicare Patient Access to Aduhelm: Biogen
April 11, 2022
- Kowa Appeals to Intellectual Property High Court in Livalo Damage Suit
April 8, 2022
- Novartis’ Japan Sales Inch Down to 320.5 Billion Yen, Revolade Rises to Best Seller
April 8, 2022
- Meiji Begins US/Canada PII Study of PDE4 Inhibitor for Plaque Psoriasis
April 8, 2022
- Japan Ethical Drug Sales Up 3.5% in February: Crecon
April 8, 2022
- Japan Pharma Sales Tick Up 2.9% in FY2021: Encise
April 8, 2022
- New Grad Hiring Down 4.4% in Spring 2022, Downtrend for Sales Reps Continues: Poll
April 7, 2022
- Jardiance Now Allowed for Use in HFpEF Patients: Label Update
April 7, 2022
- Detailing Activities via Webinars Chalk Up Double-Digit Growth in February: Intage
April 7, 2022
- Ratio of Blood-Based Gene Profiling Test at 1.4%; Cervical Cancer Most Frequently Tested: Survey
April 7, 2022
- Jardiance, Ofev Drive Up Boehringer’s Japan Sales in 2021
April 6, 2022
- Teijin, Iktos Ink Pact for AI-Based Discovery of Small Molecule Drugs
April 6, 2022
- Lundbeck Launches Japan-US PII for Multiple System Atrophy Treatment
April 6, 2022
- Pfizer Tops 2021 Global Pharma Ranking on Vaccine Boon: Jiho Tally
April 6, 2022
- Fujifilm Completes Acquisition of Atara’s US Cell Therapy Site
April 6, 2022
- Shionogi-Led Continuous Manufacturing JV Now Up and Running
April 4, 2022
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…